<Suppliers Price>

Mapatumumab

Names

[ CAS No. ]:
658052-09-6

[ Name ]:
Mapatumumab

Biological Activity

[Description]:

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Others >> Others

[In Vitro]

Mapatumumab (0.01-100 μg/mL; 4 h) shows no growth inhibition to Pediatric Preclinical Testing Program (PPTP) cell lines[1]. Mapatumumab (1-100 ng/mL; 24 h) shows significant potentiation of cytotoxicity and synergy when combined with (epirubicin) EPI for bladder cancer cells[2]. Mapatumumab (100 ng/mL; 12 h) induces significant cell apoptosis of T24, 253J and J82 cells with the combination of EPI (1 µg/mL)[2]. Mapatumumab (100 ng/mL; 6-24 h) significantly activates caspase-8, -9 and -3 with the combination of EPI (1 µg/mL)[2].

[In Vivo]

Mapatumumab (10 mg/kg; i.p. for three times) controls tumor growth when combined with irradiation[3]. Animal Model: Colo205-xenograft–bearing NMRI (nu/nu) nude mice[3] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8 Result: Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1–5) showed a pronounced tumor regrowth-delay.

[References]

[1]. Smith MA, et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54(2):307-10.

[2]. Ahmed SM, et al. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. Oncol Rep. 2015 Feb;33(2):566-72.  

[3]. Marini P, et al. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):198-202.  

Chemical & Physical Properties

No Any Chemical & Physical Properties


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.